Cargando…

Sarcoid‐like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab

Immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of non‐small cell lung cancer (NSCLC). With the increasing use of ICIs, clinicians should be familiar with their immune‐related adverse events, including sarcoid‐like reactions, which have been associated with the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takamori, Shinkichi, Furubayashi, Nobuki, Taguchi, Kenichi, Matsubara, Taichi, Fujishita, Takatoshi, Ito, Kensaku, Yamaguchi, Masafumi, Toyozawa, Ryo, Seto, Takashi, Negishi, Takahito, Nakamura, Motonobu, Okamoto, Tatsuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287006/ https://www.ncbi.nlm.nih.gov/pubmed/34002950 http://dx.doi.org/10.1111/1759-7714.14011

Ejemplares similares

Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
por: Matsubara, Taichi, et al.
Publicado: (2021)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
por: Matsubara, Taichi, et al.
Publicado: (2021)

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2022)

Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study
por: Shoji, Fumihiro, et al.
Publicado: (2022)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Acute Acalculous Cholecystitis in Patients With Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Report of Two Cases
por: Furubayashi, Nobuki, et al.
Publicado: (2014)

Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report
por: Miura, Naoko, et al.
Publicado: (2020)

Positive resection margins may not reflect the true margin in patients undergoing radical prostatectomy
por: FURUBAYASHI, NOBUKI, et al.
Publicado: (2014)

Efficacy and safety of third- and fourth-line targeted therapy in Japanese patients with metastatic renal cell carcinoma: A retrospective analysis
por: Takahito, Negishi, et al.
Publicado: (2018)

Biochemical failure after radical prostatectomy in intermediate-risk group men increases with the number of risk factors
por: Furubayashi, Nobuki, et al.
Publicado: (2017)

Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Brain cavernous hemangioma mimicking radiation‐induced necrosis in a patient with non‐small cell lung cancer
por: Takamori, Shinkichi, et al.
Publicado: (2020)

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
por: Matsubara, Taichi, et al.
Publicado: (2020)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

A Case of Cystic Retroperitoneal Dedifferentiated Liposarcoma Diagnosed by Percutaneous Image-Guided Biopsy
por: Morihara, Kaede, et al.
Publicado: (2023)

Clinical outcome of transperitoneal ureterocutaneostomy using the transverse mesocolon
por: FURUBAYASHI, NOBUKI, et al.
Publicado: (2013)

Change of genitourinary cancer patients’ perception and expectations over the course of pharmacotherapy
por: Satou, Yoshiaki, et al.
Publicado: (2022)

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Uncommon features of surgically resected ALK-positive cavitary lung adenocarcinoma: a case report
por: Takamori, Shinkichi, et al.
Publicado: (2017)

Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma
por: Negishi, Takahito, et al.
Publicado: (2020)

Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
por: Takamatsu, Dai, et al.
Publicado: (2019)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
por: Haratake, Naoki, et al.
Publicado: (2019)

The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status
por: Furubayashi, Nobuki, et al.
Publicado: (2022)

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
por: Furubayashi, Nobuki, et al.
Publicado: (2022)

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer
por: Shoji, Fumihiro, et al.
Publicado: (2022)

Pembrolizumab-Induced Sarcoid-Like Reaction in a Patient With Lung Cancer
por: Yousuf, Hira, et al.
Publicado: (2020)

Sarcoid Here, Sarcoid There, Sarcoid Everywhere
por: Iskander, Peter A, et al.
Publicado: (2023)

Pembrolizumab‐induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient
por: Honigman, Anthony D., et al.
Publicado: (2019)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Pembrolizumab-Induced Sarcoid-Like Reaction: FDG-PET Scan Interpretation in the Era of Immunotherapy
por: Malaty, Shiva, et al.
Publicado: (2020)

Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f1skrhqqv712tcqpj9s5kpepca